KUALA LUMPUR: Duopharma Biotech Bhd and the government have executed the agreement to procure insulin medicines via direct negotiation for RM375.17 million, a Bursa Malaysia filing said.
Malaysia s Ministry of Health has awarded a three-year contract to Biocon Sdn Bhd. As part of the deal, the Biocon subsidiary will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn Bhd (DMktg)
KUALA LUMPUR: Duopharma Biotech Bhd today said the government has accepted the tender offer from its wholly owned subsidiary Duopharma Marketing Sdn Bhd (DMktg) to supply Insugen, a human insulin formulation, to all Ministry of Health’s hospitals, district health offices and clinics.
KUALA LUMPUR, Dec 17 Duopharma Biotech Bhd today said the government has accepted the tender offer from its wholly owned subsidiary Duopharma Marketing Sdn Bhd (DMktg) to supply Insugen, a human insulin formulation, to all Ministry of Health’s hospitals, district health offices and clinics..
KUALA LUMPUR (Dec 29): Duopharma Biotech Bhd said the government has extended the agreement for the supply and delivery of human insulin products by one year, from Dec 2, 2020 to Dec 1, 2021, with an additional contract value of RM19.625 million.
In a filing with Bursa Malaysia today, Duopharma Biotech said the agreement was between the government, Biocon Sdn Bhd as the manufacturer, and Duopharma Marketing Sdn Bhd (DMktg), a wholly-owned subsidiary of Duopharma Biotech, as Biocon’s authorised distributor/reseller.
It said following this second additional contract value, the total contract value has been increased to RM410.725 million from RM300.04 million under the original agreement.